Tremelimumab
- Generic Name
- Tremelimumab
- Brand Names
- Imjudo, Tremelimumab AstraZeneca
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 745013-59-6
- Unique Ingredient Identifier
- QEN1X95CIX
- Background
Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tu...
- Indication
Tremelimumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also indicated in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC)
- Associated Therapies
- -
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
- Conditions
- Interventions
- First Posted Date
- 2017-02-06
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 987
- Registration Number
- NCT03043872
- Locations
- 🇺🇦
Research Site, Zaporizhzhia, Ukraine
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- Recurrent Ovarian CarcinomaRefractory Ovarian CarcinomaPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaRefractory Fallopian Tube CarcinomaRefractory Primary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2017-01-20
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT03026062
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
- First Posted Date
- 2017-01-09
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT03015129
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 33
- Registration Number
- NCT03007407
- Locations
- 🇺🇸
St. Joseph Mercy-Canton, Canton, Michigan, United States
🇺🇸Centralia Oncology Clinic, Centralia, Illinois, United States
🇺🇸UF Health Davis Cancer Pavilion and Shands Med Plaza, Gainesville, Florida, United States
Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 79
- Registration Number
- NCT02962063
- Locations
- 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
- Conditions
- Interventions
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT02953457
- Locations
- 🇺🇸
The Feinstein Institute for Medical Research/Lennox Hill Hospital, New York, New York, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Prisma Health-Upstate
- Target Recruit Count
- 150
- Registration Number
- NCT02938793
- Locations
- 🇺🇸
Greenville Health System Cancer Institute, Greenville, South Carolina, United States
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 140
- Registration Number
- NCT02879162
- Locations
- 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 180
- Registration Number
- NCT02879318
- Locations
- 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2023-12-08
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 180
- Registration Number
- NCT02870920
- Locations
- 🇨🇦
CHUQ-Pavillon Hotel-Dieu de Quebec, Quebec City, Quebec, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Hopital de la Cite-de-la-Sante, Laval, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.